Advertisement
Co Presented By
Co Presented By

GlaxoSmithKline bribed doctors, illegally boosted drug prices: China

Advertisement
FP Archives|Dec 20, 2014, 22:17:05 IST

Beijing: British drugmaker GlaxoSmithKline used travel agencies and consultancies as vehicles to bribe officials and doctors and illegally boosted the sales prices of its drugs sold in China, police said on Monday.

Since 2007 the company had transferred as much as 30 billion yuan to over 700 travel agencies and companies, Gao Feng, a police official in charge of the investigation into the company, told a news conference.

Advertisement

[caption id="attachment_955055" align="alignleft" width="400"]Reuters Reuters[/caption]

The investigation had found GlaxoSmithKline was chiefly responsible for the bribes, including instances of sexual bribery, Gao said. Four senior Chinese executives have been detained.

Police said they had taken no action against any British nationals, adding no information had been received from GSK's UK headquarters.

GSK, which says it was only told of the grounds of the investigation in early July, has said it had found no evidence of bribery or corruption in China, adding it would cooperate with the authorities.

businessMore from Business

The ministry said on Thursday that GSK executives in China had confessed to bribery and tax violations during one of a string of investigations into foreign firms in the world's second-biggest economy.

The ministry said the case against Britain's biggest drugmaker involved a large number of staff and a huge sum of money over an extended period of time, with bribes offered to Chinese government officials, medical associations, hospitals and doctors to boost sales and prices.

Advertisement

Reuters

Handpicked stories, in your inbox
Global stories. Indian perspective. Zero noise.
No Spam. Unsubscribe Any Time.
First Published:Jul 15, 2013, 09:12:57 IST
Advertisement
Advertisement
Trending Stories

BOJ seen raising interest rates by December as weak yen fuels inflation risks

Majority of economists expect Japan's central bank to deliver a 25-basis-point rate hike by year-end, with further policy tightening likely through 2027.
2 min read
Advertisement
Advertisement
Up Next